Merck and Ridgeback Biotherapeutics Covid-19 pill less effective
Merck has shared these additional analyses with the FDA and they will be presented to the FDA’s Antimicrobial Drugs Advisory Committee on Nov. 30th
Merck has shared these additional analyses with the FDA and they will be presented to the FDA’s Antimicrobial Drugs Advisory Committee on Nov. 30th
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
Subscribe To Our Newsletter & Stay Updated